developed “split‐and‐mix” strategy by combining peptides individually modified with either POI‐binding ligand or the E3‐binding ligand.[63] These nanosized peptide assemblies effectively degraded a number of targets including membrane proteins such as EGFR as well as intracellular targets estrogen receptor (ERα), AR, CDK 4/6, MEK1/2, and BCR‐ABL, all of which are critical to cancer progression and metastasis. This evidence concerns the gene ESR1 and cancer.